Pfizer and BioNTech to start human trials of Covid-19 vaccine
Tests will be on 200 healthy people in the first stage of the trial as drug companies around the world race to find a vaccine
22 April 2020 - 16:42
Berlin —Pfizer and BioNTech have secured approval for Germany’s first human clinical trials of a possible coronavirus vaccine, entering a global race to develop a defence against the pandemic.
Regulators gave the green light to test the companies’ proposed vaccine on 200 healthy people aged 18 to 55 years in a first stage, and on additional high-risk candidates in a second stage, according to a statement on Wednesday. Shares of BioNTech rose as much as 63% in Frankfurt...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.